38 results on '"Mian, O.Y."'
Search Results
2. Trial in Progress: Adaptive RADiation Therapy with Concurrent Sacituzumab Govitecan (SG) for Bladder Preservation in Patients with MIBC (RAD-SG)
3. Recursive Partitioning Analysis to Define Prognostic Groups Using a Large Single Institution Experience of Multimodality Radiation Therapy for Bladder Cancer
4. Prostate Cancer Screening Disparities in Persons Experiencing Homelessness
5. Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate
6. Primary Endpoint Analysis of a Randomized Phase III Trial of Hypofractionated vs. Conventional Post-Prostatectomy Radiotherapy: NRG Oncology GU003
7. Identification of Putative Gene-Target Modulators of Radiosensitivity in Bladder Cancer Cell Lines (BlaCCL)
8. Feasibility of Ultrasound-Based Intra-Fraction Motion Monitoring for Prostate Stereotactic Body Radiation Therapy
9. 125I Interstitial Brachytherapy with or without Androgen Deprivation Therapy among Unfavorable Risk Prostate Cancer
10. Monitoring Intra-Fraction Prostate Motion Using Kv Triggered Imaging during SBRT
11. A Comparison between External Beam Radiotherapy and Low Dose-Rate Brachytherapy for Definitive Treatment of Gleason 9&10 (ISUP 5) Prostate Cancer
12. Validation of the 2018 NCCN Prostate Cancer Risk Classification among 2,715 Patients Treated with Low Dose Rate I-125 Brachytherapy
13. Impact of Cribriform Pattern 4 and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy
14. Evaluating the 2018 NCCN Classification System for Intermediate-risk Prostate Cancer Patients Undergoing External-beam Radiation Therapy
15. 477 - Molecular characterization of neuroendocrine-like bladder cancer
16. Hydroxyflutamide Induces Androgen Receptor-Mediated DNA Damage and Radiosensitizes Prostate Cancer Cells While Preventing Induction of Pro-Growth Programs
17. The Effect of the Timing of Biochemical Failure after External Beam Radiation Therapy or Low Dose-rate Brachytherapy for Definitive Prostate Cancer Treatment
18. Achieving “Zero PSA” Following Post-Prostatectomy Radiation Therapy for Lymph Node Positive Prostate Cancer in the Ultrasensitive PSA Era
19. Tumor Gene Expression Profiling in Prostate Cancer (PCa) Identifies Molecular Taxonomies Associated with Node Positivity and Quantitative Imaging Features on Multiparametric MRI (mpMRI)
20. Ten-Year Outcomes and Toxicity with Moderately Hypofractionated (70 Gy in 28 fractions) Intensity-Modulated Radiation Therapy for Localized Prostate Cancer.
21. Prostate SBRT Intrafraction Monitoring With Transperineal Ultrasound
22. Molecular Profiling of Small Cell Bladder Cancer Reveals Gene Expression Determinants of an Aggressive Phenotype
23. Stereotactic Body Radiation Therapy in Pancreas Adenocarcinoma Demonstrates Minimal Acute and Late Toxicity
24. Reductions in Prostatic and Urethral Doses Are Associated With Less Acute Morbidity in Patients Undergoing Pd-103 Brachytherapy: Substantiation of the Rationale for Focal Therapy
25. A Prospective Study Evaluating Registered Ultrasound and Fluoroscopy (RUF) for Intraoperative Dose Calculation: Improved Accuracy Compared to Current Ultrasound-based Intraoperative Dosimetry
26. Pancreas Stereotactic Body Radiation Therapy Demonstrates Minimal Acute Treatment-Related Toxicity
27. Neoadjuvant Stereotactic Body Radiation Therapy Dosimetric Parameters Predict for Pathologic Outcomes and Survival in Pancreas Adenocarcinoma
28. Preference to Spare Critical Anatomy Near Gross Tumor Volume Is Associated With Poor Pathologic Complete Response With Breath Hold–Based Neoadjuvant Stereotactic Body Radiation Therapy for Pancreatic Cancer
29. Volumetric Assessment of Tumor Vessel Interaction Is a Predictor of Surgical Candidacy in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Treated With Stereotactic Body Radiation Therapy
30. Partial Agonist Activity of Hydroxyflutamide Induces AR- and TOP2B-dependent DNA Double Strand Breaks and Radiosensitizes Prostate Cancer Cells
31. A Novel Technology for Noninvasive Detection of Prostate Cancer DNA in the Blood and Urine of Men With High-Risk PCA Receiving Radiation Therapy and Androgen Suppression
32. Dosimetric Parameters Correlate With Node Negative Resection in Borderline and Initially Unresectable Pancreatic Adenocarcinoma Patients Treated With Stereotactic Body Radiation Therapy Followed by Surgical Resection
33. Total Lesion Glycolysis as a Predictor of Pathologic Outcomes Locally Advanced and Borderline Resectable Patients Undergoing Surgery After Preoperative Stereotactic Body Radiation Therapy
34. Generation of DNA Double Strand Breaks in Prostate Cancer Cells by Androgen Receptor Antagonists, Hydroxyflutamide and Bicalutamide
35. Dosimetric Predictors of Sexual Function Decline Following Low-Dose-Rate Brachytherapy for Prostate Cancer (PCa)
36. Reduced Lymphocytopenia Following Stereotactic Body Radiation Therapy (SBRT) for Spine Metastases Compared With Conventional Radiation Therapy (CRT)
37. Dosimetric Parameters Predicting Late Toxicity in Stereotactic Body Radiation Therapy (SBRT) for Pancreatic Cancer
38. Timely Radiosurgery for Spine Metastases per RTOG 0613 Guidelines Using a Rapidly Deployable Automated Planning Script
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.